文献速递MDS 与骨髓增殖性肿瘤

炎症小体激活后释放的氧化线粒体DNA可作为骨髓增生异常综合征的疾病生物标志物

Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.
PubMed 文献 · Blood Adv · 2021-01-01

该研究利用常见MDS体细胞基因突变的小鼠模型骨髓细胞及MDS原代样本,发现焦亡时释放氧化线粒体DNA(ox-mtDNA)。MDS外周血浆ox-mtDNA显著高于健康供者,低危MDS高于高危MDS,且除慢性淋巴细胞白血病(CLL)外高于其他血液恶性肿瘤。ROC/AUC分析显示ox-mtDNA对MDS具有敏感且特异的生物标志物价值。

要点

  • MDS血浆ox-mtDNA显著高于健康供者,低危MDS高于高危MDS。
  • 除CLL外,MDS血浆ox-mtDNA显著高于其他研究的血液恶性肿瘤。
  • ox-mtDNA与S100A9、S100A8及CARD斑点等已知警报素水平正相关。

核心结论

  • 炎症小体激活后释放至细胞外的可定量ox-mtDNA可作为MDS的生物标志物,并反映焦亡细胞死亡的程度。

研究设计与样本

  • 研究使用常见MDS体细胞基因突变的小鼠模型永生化骨髓细胞及MDS原代样本。
  • 比较MDS外周血浆与健康供者、其他血液恶性肿瘤及反应性状况的血浆ox-mtDNA水平。

主要发现

  • ox-mtDNA在焦亡时释放。
  • MDS外周血浆ox-mtDNA显著高于健康供者血浆。
  • 低危MDS的ox-mtDNA显著高于高危MDS,与低危患者焦亡细胞比例更高一致。
  • 除CLL外,MDS血浆ox-mtDNA显著高于所有其他研究的血液恶性肿瘤。
  • ox-mtDNA与S100A9、S100A8及CARD斑点水平呈显著正相关。

关键数值与推荐

  • ox-mtDNA区分MDS与健康供者的ROC/AUC为0.964。
  • ox-mtDNA区分MDS与除CLL外其他血液恶性肿瘤的ROC/AUC为0.893。
  • ox-mtDNA区分MDS与反应性状况的ROC/AUC为0.940。

临床怎么用

  • ox-mtDNA有望作为辅助生物标志物用于MDS的疾病鉴别诊断。
  • ox-mtDNA水平可能反映MDS患者焦亡细胞死亡的程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem cell malignancies that can phenotypically resemble other hematologic disorders. Thus, tools that may add to current diagnostic practices could aid in disease discrimination. Constitutive innate immune activation is a pathogenetic driver of ineffective hematopoiesis in MDS through Nod-like receptor protein 3 (NLRP3)-inflammasome-induced pyroptotic cell death. Oxidized mitochondrial DNA (ox-mtDNA) is released upon cytolysis, acts as a danger signal, and triggers inflammasome oligomerization via DNA sensors. By using immortalized bone marrow cells from murine models of common MDS somatic gene mutations and MDS primary samples, we demonstrate that ox-mtDNA is released upon pyroptosis. ox-mtDNA was significantly increased in MDS peripheral blood (PB) plasma compared with the plasma of healthy donors, and it was significantly higher in lower-risk MDS vs higher-risk MDS, consistent with the greater pyroptotic cell fraction in lower-risk patients. Furthermore, ox-mtDNA was significantly higher in MDS PB plasma compared with all other hematologic malignancies studied, with the exception of chronic lymphocytic leukemia (CLL). Receiver operating characteristic/area under the curve (ROC/AUC) analysis demonstrated that ox-mtDNA is a sensitive and specific biomarker for patients with MDS compared with healthy donors (AUC, 0.964), other hematologic malignancies excluding CLL (AUC, 0.893), and reactive conditions (AUC, 0.940). ox-mtDNA positively and significantly correlated with levels of known alarmins S100A9, S100A8, and apoptosis-associated speck-like protein containing caspase recruitment domain (CARD) specks, which provide an index of medullary pyroptosis. Collectively, these data indicate that quantifiable ox-mtDNA released into the extracellular space upon inflammasome activation serves as a biomarker for MDS and the magnitude of pyroptotic cell death.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ward GA, McGraw KL, Abbas-Aghababazadeh F, et al. Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Adv. 2021. PMID: 33890980. doi:10.1182/bloodadvances.2020003475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。